vs
Side-by-side financial comparison of REGENXBIO Inc. (RGNX) and REGIS CORP (RGS). Click either name above to swap in a different company.
REGIS CORP is the larger business by last-quarter revenue ($57.1M vs $30.3M, roughly 1.9× REGENXBIO Inc.). REGIS CORP runs the higher net margin — 0.8% vs -221.3%, a 222.1% gap on every dollar of revenue. On growth, REGENXBIO Inc. posted the faster year-over-year revenue change (43.0% vs 22.3%). REGIS CORP produced more free cash flow last quarter ($891.0K vs $-52.8M). Over the past eight quarters, REGENXBIO Inc.'s revenue compounded faster (39.4% CAGR vs 7.8%).
REGENXBIO Inc. is a clinical-stage biotechnology firm focused on gene therapy for rare severe genetic diseases. It licenses its proprietary AAV vector technology to global biopharma partners, and advances its own pipeline targeting ophthalmology, metabolic and neurodegenerative disorders.
REGIS CORPRGSEarnings & Financial Report
Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.
RGNX vs RGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $30.3M | $57.1M |
| Net Profit | $-67.1M | $456.0K |
| Gross Margin | — | — |
| Operating Margin | -190.0% | 10.8% |
| Net Margin | -221.3% | 0.8% |
| Revenue YoY | 43.0% | 22.3% |
| Net Profit YoY | -31.2% | -94.0% |
| EPS (diluted) | $-1.30 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.3M | $57.1M | ||
| Q3 25 | $29.7M | $59.0M | ||
| Q2 25 | $21.4M | $60.4M | ||
| Q1 25 | $89.0M | $57.0M | ||
| Q4 24 | $21.2M | $46.7M | ||
| Q3 24 | $24.2M | $46.1M | ||
| Q2 24 | $22.3M | $49.4M | ||
| Q1 24 | $15.6M | $49.2M |
| Q4 25 | $-67.1M | $456.0K | ||
| Q3 25 | $-61.9M | $1.4M | ||
| Q2 25 | $-70.9M | $116.5M | ||
| Q1 25 | $6.1M | $250.0K | ||
| Q4 24 | $-51.2M | $7.6M | ||
| Q3 24 | $-59.6M | $-853.0K | ||
| Q2 24 | $-53.0M | $91.2M | ||
| Q1 24 | $-63.3M | $-2.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 70.2% | — | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 52.5% | — | ||
| Q1 24 | 72.6% | — |
| Q4 25 | -190.0% | 10.8% | ||
| Q3 25 | -176.3% | 10.0% | ||
| Q2 25 | -296.3% | 12.1% | ||
| Q1 25 | 13.6% | 8.8% | ||
| Q4 24 | -242.1% | 11.8% | ||
| Q3 24 | -256.6% | 4.6% | ||
| Q2 24 | -251.3% | — | ||
| Q1 24 | -408.8% | 8.3% |
| Q4 25 | -221.3% | 0.8% | ||
| Q3 25 | -208.3% | 2.3% | ||
| Q2 25 | -331.8% | 192.9% | ||
| Q1 25 | 6.8% | 0.4% | ||
| Q4 24 | -241.3% | 16.4% | ||
| Q3 24 | -246.3% | -1.9% | ||
| Q2 24 | -237.7% | 184.7% | ||
| Q1 24 | -405.4% | -4.7% |
| Q4 25 | $-1.30 | $0.16 | ||
| Q3 25 | $-1.20 | $0.49 | ||
| Q2 25 | $-1.38 | $43.67 | ||
| Q1 25 | $0.12 | $0.08 | ||
| Q4 24 | $-0.99 | $2.71 | ||
| Q3 24 | $-1.17 | $-0.36 | ||
| Q2 24 | $-1.05 | $38.40 | ||
| Q1 24 | $-1.38 | $-1.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $230.1M | $18.4M |
| Total DebtLower is stronger | — | $113.3M |
| Stockholders' EquityBook value | $102.7M | $188.7M |
| Total Assets | $453.0M | $588.3M |
| Debt / EquityLower = less leverage | — | 0.60× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.1M | $18.4M | ||
| Q3 25 | $274.2M | $16.6M | ||
| Q2 25 | $323.3M | $17.0M | ||
| Q1 25 | $267.9M | $13.3M | ||
| Q4 24 | $234.7M | $10.2M | ||
| Q3 24 | $255.5M | $6.3M | ||
| Q2 24 | $290.4M | $10.1M | ||
| Q1 24 | $338.7M | $5.9M |
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
| Q4 25 | $102.7M | $188.7M | ||
| Q3 25 | $161.5M | $187.6M | ||
| Q2 25 | $213.7M | $185.6M | ||
| Q1 25 | $274.2M | $68.6M | ||
| Q4 24 | $259.7M | $66.7M | ||
| Q3 24 | $301.4M | $56.4M | ||
| Q2 24 | $348.3M | $56.8M | ||
| Q1 24 | $390.7M | $-35.8M |
| Q4 25 | $453.0M | $588.3M | ||
| Q3 25 | $525.2M | $592.1M | ||
| Q2 25 | $581.0M | $599.0M | ||
| Q1 25 | $490.9M | $511.2M | ||
| Q4 24 | $466.0M | $530.1M | ||
| Q3 24 | $519.1M | $508.9M | ||
| Q2 24 | $569.4M | $530.5M | ||
| Q1 24 | $629.2M | $543.7M |
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.3M | $1.7M |
| Free Cash FlowOCF − Capex | $-52.8M | $891.0K |
| FCF MarginFCF / Revenue | -174.0% | 1.6% |
| Capex IntensityCapex / Revenue | 1.7% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 3.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-126.4M | $14.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.3M | $1.7M | ||
| Q3 25 | $-56.0M | $2.3M | ||
| Q2 25 | $-49.3M | $6.8M | ||
| Q1 25 | $33.6M | $6.2M | ||
| Q4 24 | $-31.6M | $2.1M | ||
| Q3 24 | $-40.5M | $-1.3M | ||
| Q2 24 | $-45.5M | $5.1M | ||
| Q1 24 | $-55.5M | $-277.0K |
| Q4 25 | $-52.8M | $891.0K | ||
| Q3 25 | $-56.5M | $1.9M | ||
| Q2 25 | $-49.7M | $6.2M | ||
| Q1 25 | $32.6M | $5.9M | ||
| Q4 24 | $-32.7M | $1.7M | ||
| Q3 24 | $-40.9M | $-1.4M | ||
| Q2 24 | $-46.0M | $5.1M | ||
| Q1 24 | $-56.0M | $-326.0K |
| Q4 25 | -174.0% | 1.6% | ||
| Q3 25 | -189.9% | 3.2% | ||
| Q2 25 | -232.8% | 10.3% | ||
| Q1 25 | 36.6% | 10.3% | ||
| Q4 24 | -154.2% | 3.6% | ||
| Q3 24 | -168.9% | -3.0% | ||
| Q2 24 | -206.2% | 10.3% | ||
| Q1 24 | -358.5% | -0.7% |
| Q4 25 | 1.7% | 1.4% | ||
| Q3 25 | 1.7% | 0.7% | ||
| Q2 25 | 1.8% | 0.9% | ||
| Q1 25 | 1.2% | 0.6% | ||
| Q4 24 | 5.1% | 0.9% | ||
| Q3 24 | 1.3% | 0.0% | ||
| Q2 24 | 2.1% | 0.0% | ||
| Q1 24 | 3.6% | 0.1% |
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | 5.53× | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
